All roads lead to PP2A: Exploiting the therapeutic potential of this phosphatase

FEBS Journal

Volumn 283, Issue 6, 2016, Pages 1004-1024

  Sangodkar, Jaya ^a   Farrington, Caroline C ^b   McClinch, Kimberly ^a   Galsky, Matthew D ^a   Kastrinsky, David B ^a   Narla, Goutham ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cancer; cancer biology; cell signaling; CIP2A; drug development; PP2A; protein phosphatases; SET; structural biology; tumor suppressors

Indexed keywords

CALCINEURIN; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE 4; UNCLASSIFIED DRUG; ENZYME INHIBITOR; PHOSPHOPROTEIN PHOSPHATASE 2; PROTEIN SUBUNIT; TUMOR SUPPRESSOR PROTEIN;

CARBOXY TERMINAL SEQUENCE; DISEASE ACTIVITY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME STRUCTURE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; STOICHIOMETRY; CHEMISTRY; ENZYME ACTIVE SITE; ENZYMOLOGY; GENE DELETION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR MODEL; MUTATION; NEOPLASMS; PHOSPHORYLATION; PROTEIN SUBUNIT;

CATALYTIC DOMAIN; ENZYME INHIBITORS; GENE DELETION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, MOLECULAR; MUTATION; NEOPLASMS; PHOSPHORYLATION; PROTEIN PHOSPHATASE 2; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN SUBUNITS; TUMOR SUPPRESSOR PROTEINS;

EID: 84961789012     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13573     Document Type: Review

References (210)

1. Brautigan DL, (2013) Protein Ser/Thr phosphatases-the ugly ducklings of cell signalling. FEBS J 280, 324-345.
2. Shi Y, (2009) Serine/threonine phosphatases: mechanism through structure. Cell 139, 468-484.
3. Stone SR, Hofsteenge J, &, Hemmings BA, (1987) Molecular cloning of cDNAs encoding two isoforms of the catalytic subunit of protein phosphatase 2A. Biochemistry 26, 7215-7220.
4. Khew-Goodall Y, &, Hemmings BA, (1988) Tissue-specific expression of mRNAs encoding alpha- and beta-catalytic subunits of protein phosphatase 2A. FEBS Lett 238, 265-268.
5. Eichhorn PJ, Creyghton MP, &, Bernards R, (2009) Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta 1795, 1-15.
6. Andrade MA, &, Bork P, (1995) HEAT repeats in the Huntington's disease protein. Nat Genet 11, 115-116.
7. Groves MR, Hanlon N, Turowski P, Hemmings BA, &, Barford D, (1999) The structure of the protein phosphatase 2A PR65/A subunit reveals the conformation of its 15 tandemly repeated HEAT motifs. Cell 96, 99-110.
8. Wozniak E, Oldziej S, &, Ciarkowski J, (2000) Molecular modeling of the catalytic domain of serine/threonine phosphatase-1 with the Zn2+ and Mn2+ di-nuclear ion centers in the active site. Comput Chem 24, 381-390.
9. Xing Y, Xu Y, Chen Y, Jeffrey PD, Chao Y, Lin Z, Li Z, Strack S, Stock JB, &, Shi Y, (2006) Structure of protein phosphatase 2A core enzyme bound to tumor-inducing toxins. Cell 127, 341-353.
10. Longin S, Zwaenepoel K, Louis JV, Dilworth S, Goris J, &, Janssens V, (2007) Selection of protein phosphatase 2A regulatory subunits is mediated by the C terminus of the catalytic Subunit. J Biol Chem 282, 26971-26980.
11. Kamibayashi C, Lickteig RL, Estes R, Walter G, &, Mumby MC, (1992) Expression of the A subunit of protein phosphatase 2A and characterization of its interactions with the catalytic and regulatory subunits. J Biol Chem 267, 21864-21872.
12. McCright B, Rivers AM, Audlin S, &, Virshup DM, (1996) The B56 family of protein phosphatase 2A (PP2A) regulatory subunits encodes differentiation-induced phosphoproteins that target PP2A to both nucleus and cytoplasm. J Biol Chem 271, 22081-22089.
13. Cho US, &, Xu W, (2007) Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme. Nature 445, 53-57.
14. Wlodarchak N, Guo F, Satyshur KA, Jiang L, Jeffrey PD, Sun T, Stanevich V, Mumby MC, &, Xing Y, (2013) Structure of the Ca2+-dependent PP2A heterotrimer and insights into Cdc6 dephosphorylation. Cell Res 23, 931-946.
15. Gentry MS, &, Hallberg RL, (2002) Localization of Saccharomyces cerevisiae protein phosphatase 2A subunits throughout mitotic cell cycle. Mol Biol Cell 13, 3477-3492.
16. Ghaemmaghami S, Huh WK, Bower K, Howson RW, Belle A, Dephoure N, O'Shea EK, &, Weissman JS, (2003) Global analysis of protein expression in yeast. Nature 425, 737-741.
17. Sents W, Ivanova E, Lambrecht C, Haesen D, &, Janssens V, (2013) The biogenesis of active protein phosphatase 2A holoenzymes: a tightly regulated process creating phosphatase specificity. FEBS J 280, 644-661.
18. Beck M, Schmidt A, Malmstroem J, Claassen M, Ori A, Szymborska A, Herzog F, Rinner O, Ellenberg J, &, Aebersold R, (2011) The quantitative proteome of a human cell line. Mol Syst Biol 7, 549.
19. Li X, Scuderi A, Letsou A, &, Virshup DM, (2002) B56-associated protein phosphatase 2A is required for survival and protects from apoptosis in Drosophila melanogaster. Mol Cell Biol 22, 3674-3684.
20. Silverstein AM, Barrow CA, Davis AJ, &, Mumby MC, (2002) Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits. Proc Natl Acad Sci USA 99, 4221-4226.
21. Strack S, Cribbs JT, &, Gomez L, (2004) Critical role for protein phosphatase 2A heterotrimers in mammalian cell survival. J Biol Chem 279, 47732-47739.
22. Janssens V, Jordens J, Stevens I, Van Hoof C, Martens E, De Smedt H, Engelborghs Y, Waelkens E, &, Goris J, (2003) Identification and functional analysis of two Ca2+-binding EF-hand motifs in the B"/PR72 subunit of protein phosphatase 2A. J Biol Chem 278, 10697-10706.
23. Chen W, Arroyo JD, Timmons JC, Possemato R, &, Hahn WC, (2005) Cancer-associated PP2A Aalpha subunits induce functional haploinsufficiency and tumorigenicity. Cancer Res 65, 8183-8192.
24. Liu F, Grundke-Iqbal I, Iqbal K, &, Gong CX, (2005) Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 22, 1942-1950.
25. Gong CX, Singh TJ, Grundke-Iqbal I, &, Iqbal K, (1993) Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem 61, 921-927.
26. Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, &, Lee VM, (2001) PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp Neurol 168, 402-412.
27. Sontag E, Luangpirom A, Hladik C, Mudrak I, Ogris E, Speciale S, &, White CL 3rd, (2004) Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology. J Neuropathol Exp Neurol 63, 287-301.
28. Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I, &, Iqbal K, (1995) Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem 65, 732-738.
29. Liu R, Zhou XW, Tanila H, Bjorkdahl C, Wang JZ, Guan ZZ, Cao Y, Gustafsson JA, Winblad B, &, Pei JJ, (2008) Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology. J Cell Mol Med 12, 241-257.
30. Voronkov M, Braithwaite SP, &, Stock JB, (2011) Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer's disease. Future Med Chem 3, 821-833.
31. Tian Q, &, Wang J, (2002) Role of serine/threonine protein phosphatase in Alzheimer's disease. Neurosignals 11, 262-269.
32. Begum N, &, Ragolia L, (1996) cAMP counter-regulates insulin-mediated protein phosphatase-2A inactivation in rat skeletal muscle cells. J Biol Chem 271, 31166-31171.
33. Hojlund K, Poulsen M, Staehr P, Brusgaard K, &, Beck-Nielsen H, (2002) Effect of insulin on protein phosphatase 2A expression in muscle in type 2 diabetes. Eur J Clin Invest 32, 918-923.
34. Lipina C, &, Hundal HS, (2014) Carnosic acid stimulates glucose uptake in skeletal muscle cells via a PME-1/PP2A/PKB signalling axis. Cell Signal 26, 2343-2349.
35. Wallace AM, Hardigan A, Geraghty P, Salim S, Gaffney A, Thankachen J, Arellanos L, D'Armiento JM, &, Foronjy RF, (2012) Protein phosphatase 2A regulates innate immune and proteolytic responses to cigarette smoke exposure in the lung. Toxicol Sci 126, 589-599.
36. Kirchhefer U, Brekle C, Eskandar J, Isensee G, Kucerova D, Muller FU, Pinet F, Schulte JS, Seidl MD, &, Boknik P, (2014) Cardiac function is regulated by B56alpha-mediated targeting of protein phosphatase 2A (PP2A) to contractile relevant substrates. J Biol Chem 289, 33862-33873.
37. Perrotti D, &, Neviani P, (2013) Protein phosphatase 2A: a target for anticancer therapy. Lancet Oncol 14, e229-e238.
38. Sablina AA, &, Hahn WC, (2008) SV40 small T antigen and PP2A phosphatase in cell transformation. Cancer Metastasis Rev 27, 137-146.
39. Ruediger R, Ruiz J, &, Walter G, (2011) Human cancer-associated mutations in the Aalpha subunit of protein phosphatase 2A increase lung cancer incidence in Aalpha knock-in and knockout mice. Mol Cell Biol 31, 3832-3844.
40. Ruediger R, Pham HT, &, Walter G, (2001) Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene. Oncogene 20, 1892-1899.
41. Calin GA, di Iasio MG, Caprini E, Vorechovsky I, Natali PG, Sozzi G, Croce CM, Barbanti-Brodano G, Russo G, &, Negrini M, (2000) Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene 19, 1191-1195.
42. Ruediger R, Pham HT, &, Walter G, (2001) Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene. Oncogene 20, 10-15.
43. McConechy MK, Anglesio MS, Kalloger SE, Yang W, Senz J, Chow C, Heravi-Moussavi A, Morin GB, &, Mes-Masson AM, Australian Ovarian Cancer Study Group, Carey MS, McAlpine JN, Kwon JS, Prentice LM, Boyd N, Shah SP, Gilks CB, &, Huntsman DG, (2011) Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol 223, 567-573.
44. Shih Ie M, &, Wang TL, (2011) Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma. J Pathol 224, 1-4.
45. Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, Chaudhuri S, Guan Y, Janakiraman V, Jaiswal BS, et al,. (2012) Recurrent R-spondin fusions in colon cancer. Nature 488, 660-664.
46. Jones S, Wang TL, Shih Ie M, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, et al,. (2010) Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330, 228-231.
47. Nagendra DC, Burke J 3rd, Maxwell GL, &, Risinger JI, (2012) PPP2R1A mutations are common in the serous type of endometrial cancer. Mol Carcinog 51, 826-831.
48. Colella S, Ohgaki H, Ruediger R, Yang F, Nakamura M, Fujisawa H, Kleihues P, &, Walter G, (2001) Reduced expression of the Aalpha subunit of protein phosphatase 2A in human gliomas in the absence of mutations in the Aalpha and Abeta subunit genes. Int J Cancer 93, 798-804.
49. Wang SS, Esplin ED, Li JL, Huang L, Gazdar A, Minna J, &, Evans GA, (1998) Alterations of the PPP2R1B gene in human lung and colon cancer. Science 282, 284-287.
50. Takagi Y, Futamura M, Yamaguchi K, Aoki S, Takahashi T, &, Saji S, (2000) Alterations of the PPP2R1B gene located at 11q23 in human colorectal cancers. Gut 47, 268-271.
51. Esplin ED, Ramos P, Martinez B, Tomlinson GE, Mumby MC, &, Evans GA, (2006) The glycine 90 to aspartate alteration in the Abeta subunit of PP2A (PPP2R1B) associates with breast cancer and causes a deficit in protein function. Genes Chromosom Cancer 45, 182-190.
52. Baysal BE, Willett-Brozick JE, Taschner PE, Dauwerse JG, Devilee P, &, Devlin B, (2001) A high-resolution integrated map spanning the SDHD gene at 11q23: a 1.1-Mb BAC contig, a partial transcript map and 15 new repeat polymorphisms in a tumour-suppressor region. Eur J Hum Genet 9, 121-129.
53. Ramaswamy K, Spitzer B, &, Kentsis A, (2015) Therapeutic Re-Activation of Protein Phosphatase 2A in Acute Myeloid Leukemia. Front Oncol 5, 16.
54. Kalla C, Scheuermann MO, Kube I, Schlotter M, Mertens D, Dohner H, Stilgenbauer S, &, Lichter P, (2007) Analysis of 11q22-q23 deletion target genes in B-cell chronic lymphocytic leukaemia: evidence for a pathogenic role of NPAT, CUL5, and PPP2R1B. Eur J Cancer 43, 1328-1335.
55. Chou H-C, Chen C-H, Lee H-S, Lee C-Z, Huang G-T, Yang P-M, Lee P-H, &, Sheu J-C, (2007) Alterations of tumour suppressor PP2R1B in hepatocellular carcinoma. Cancer Lett 253, 138-143.
56. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al,. (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352.
57. Cheng Y, Liu W, Kim ST, Sun J, Lu L, Zheng SL, Isaacs WB, &, Xu J, (2011) Evaluation of PPP2R2A as a prostate cancer susceptibility gene: a comprehensive germline and somatic study. Cancer Genet 204, 375-381.
58. Mosca L, Musto P, Todoerti K, Barbieri M, Agnelli L, Fabris S, Tuana G, Lionetti M, Bonaparte E, Sirchia SM, et al,. (2013) Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. Am J Hematol 88, 16-23.
59. Ruvolo PP, Qui YH, Coombes KR, Zhang N, Ruvolo VR, Borthakur G, Konopleva M, Andreeff M, &, Kornblau SM, (2011) Low expression of PP2A regulatory subunit B55alpha is associated with T308 phosphorylation of AKT and shorter complete remission duration in acute myeloid leukemia patients. Leukemia 25, 1711-1717.
60. Muggerud AA, Ronneberg JA, Warnberg F, Botling J, Busato F, Jovanovic J, Solvang H, Bukholm I, Borresen-Dale AL, Kristensen VN, et al,. (2010) Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res 12, R3.
61. Tan J, Lee PL, Li Z, Jiang X, Lim YC, Hooi SC, &, Yu Q, (2010) B55beta-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell 18, 459-471.
62. Bluemn EG, Spencer ES, Mecham B, Gordon RR, Coleman I, Lewinshtein D, Mostaghel E, Zhang X, Annis J, Grandori C, et al,. (2013) PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality. Mol Cancer Res 11, 568-578.
63. Fan YL, Chen L, Wang J, Yao Q, &, Wan JQ, (2013) Over expression of PPP2R2C inhibits human glioma cells growth through the suppression of mTOR pathway. FEBS Lett 587, 3892-3897.
64. Mannava S, Omilian AR, Wawrzyniak JA, Fink EE, Zhuang D, Miecznikowski JC, Marshall JR, Soengas MS, Sears RC, Morrison CD, et al,. (2012) PP2A-B56alpha controls oncogene-induced senescence in normal and tumor human melanocytic cells. Oncogene 31, 1484-1492.
65. Deichmann M, Thome M, Benner A, Egner U, Hartschuh W, &, Naher H, (2002) PTEN/MMAC1 expression in melanoma resection specimens. Br J Cancer 87, 1431-1436.
66. Shouse GP, Nobumori Y, &, Liu X, (2010) A B56gamma mutation in lung cancer disrupts the p53-dependent tumor-suppressor function of protein phosphatase 2A. Oncogene 29, 3933-3941.
67. Grochola LF, Vazquez A, Bond EE, Wurl P, Taubert H, Muller TH, Levine AJ, &, Bond GL, (2009) Recent natural selection identifies a genetic variant in a regulatory subunit of protein phosphatase 2A that associates with altered cancer risk and survival. Clin Cancer Res 15, 6301-6308.
68. Sallman DA, Wei S, &, List A, (2014) PP2A: the Achilles heal in MDS with 5q deletion. Front Oncol 4, 264.
69. Singh AP, Bafna S, Chaudhary K, Venkatraman G, Smith L, Eudy JD, Johansson SL, Lin MF, &, Batra SK, (2008) Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. Cancer Lett 259, 28-38.
70. Bhardwaj A, Singh S, Srivastava SK, Honkanen RE, Reed E, &, Singh AP, (2011) Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications. Mol Cancer Ther 10, 720-731.
71. Baysal BE, Farr JE, Goss JR, Devlin B, &, Richard CW 3rd, (1998) Genomic organization and precise physical location of protein phosphatase 2A regulatory subunit A beta isoform gene on chromosome band 11q23. Gene 217, 107-116.
72. Kiely M, &, Kiely PA, (2015) PP2A: the wolf in Sheep's clothing? Cancers (Basel) 7, 648-669.
73. Sablina AA, Chen W, Arroyo JD, Corral L, Hector M, Bulmer SE, DeCaprio JA, &, Hahn WC, (2007) The tumor suppressor PP2A Abeta regulates the RalA GTPase. Cell 129, 969-982.
74. Hemmings BA, Adams-Pearson C, Maurer F, Muller P, Goris J, Merlevede W, Hofsteenge J, &, Stone SR, (1990) alpha- and beta-forms of the 65-kDa subunit of protein phosphatase 2A have a similar 39 amino acid repeating structure. Biochemistry 29, 3166-3173.
75. Ito A, Kataoka TR, Watanabe M, Nishiyama K, Mazaki Y, Sabe H, Kitamura Y, &, Nojima H, (2000) A truncated isoform of the PP2A B56 subunit promotes cell motility through paxillin phosphorylation. EMBO J 19, 562-571.
76. De Baere I, Derua R, Janssens V, Van Hoof C, Waelkens E, Merlevede W, &, Goris J, (1999) Purification of porcine brain protein phosphatase 2A leucine carboxyl methyltransferase and cloning of the human homologue. Biochemistry 38, 16539-16547.
77. Ogris E, Du X, Nelson KC, Mak EK, Yu XX, Lane WS, &, Pallas DC, (1999) A protein phosphatase methylesterase (PME-1) is one of several novel proteins stably associating with two inactive mutants of protein phosphatase 2A. J Biol Chem 274, 14382-14391.
78. Xing YN, Li Z, Chen Y, Stock JB, Jeffrey PD, &, Shi YG, (2008) Structural mechanism of demethylation and inactivation of protein phosphatase 2A. Cell 133, 154-163.
79. Ortega-Gutierrez S, Leung D, Ficarro S, Peters EC, &, Cravatt BF, (2008) Targeted disruption of the PME-1 gene causes loss of demethylated PP2A and perinatal lethality in mice. PLoS One 3, e2486.
80. Lee JA, &, Pallas DC, (2007) Leucine carboxyl methyltransferase-1 is necessary for normal progression through mitosis in mammalian cells. J Biol Chem 282, 30974-30984.
81. Xia X, Gholkar A, Senese S, &, Torres JZ, (2015) A LCMT1-PME-1 methylation equilibrium controls mitotic spindle size. Cell Cycle 14, 1938-1947.
82. Ikehara T, Ikehara S, Imamura S, Shinjo F, &, Yasumoto T, (2007) Methylation of the C-terminal leucine residue of the PP2A catalytic subunit is unnecessary for the catalytic activity and the binding of regulatory subunit (PR55/B). Biochem Biophys Res Commun 354, 1052-1057.
83. Janssens V, Longin S, &, Goris J, (2008) PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail). Trends Biochem Sci 33, 113-121.
84. Gentry MS, Li Y, Wei H, Syed FF, Patel SH, Hallberg RL, &, Pallas DC, (2005) A novel assay for protein phosphatase 2A (PP2A) complexes in vivo reveals differential effects of covalent modifications on different Saccharomyces cerevisiae PP2A heterotrimers. Eukaryot Cell 4, 1029-1040.
85. Wu J, Tolstykh T, Lee J, Boyd K, Stock JB, &, Broach JR, (2000) Carboxyl methylation of the phosphoprotein phosphatase 2A catalytic subunit promotes its functional association with regulatory subunits in vivo. EMBO J 19, 5672-5681.
86. Yu XX, Du X, Moreno CS, Green RE, Ogris E, Feng Q, Chou L, McQuoid MJ, &, Pallas DC, (2001) Methylation of the protein phosphatase 2A catalytic subunit is essential for association of Balpha regulatory subunit but not SG2NA, striatin, or polyomavirus middle tumor antigen. Mol Biol Cell 12, 185-199.
87. Xu Y, Chen Y, Zhang P, Jeffrey PD, &, Shi Y, (2008) Structure of a protein phosphatase 2A holoenzyme: insights into B55-mediated Tau dephosphorylation. Mol Cell 31, 873-885.
88. Sontag JM, Nunbhakdi-Craig V, Montgomery L, Arning E, Bottiglieri T, &, Sontag E, (2008) Folate deficiency induces in vitro and mouse brain region-specific downregulation of leucine carboxyl methyltransferase-1 and protein phosphatase 2A B(alpha) subunit expression that correlate with enhanced tau phosphorylation. J Neurosci 28, 11477-11487.
89. Sontag JM, Nunbhakdi-Craig V, Mitterhuber M, Ogris E, &, Sontag E, (2010) Regulation of protein phosphatase 2A methylation by LCMT1 and PME-1 plays a critical role in differentiation of neuroblastoma cells. J Neurochem 115, 1455-1465.
90. Sontag JM, Nunbhakdi-Craig V, &, Sontag E, (2013) Leucine carboxyl methyltransferase 1 (LCMT1)-dependent methylation regulates the association of protein phosphatase 2A and Tau protein with plasma membrane microdomains in neuroblastoma cells. J Biol Chem 288, 27396-27405.
91. Yang CC, Kuai XX, Li YL, Zhang L, Yu JC, &, Li L, (2013) Cornel iridoid glycoside attenuates tau hyperphosphorylation by inhibition of PP2A demethylation. Evid Based Complement Alternat Med 2013, 108486.
92. Longin S, Jordens J, Martens E, Stevens I, Janssens V, Rondelez E, De Baere I, Derua R, Waelkens E, Goris J, et al,. (2004) An inactive protein phosphatase 2A population is associated with methylesterase and can be re-activated by the phosphotyrosyl phosphatase activator. Biochem J 380, 111-119.
93. Fellner T, Lackner DH, Hombauer H, Piribauer P, Mudrak I, Zaragoza K, Juno C, &, Ogris E, (2003) A novel and essential mechanism determining specificity and activity of protein phosphatase 2A (PP2A) in vivo. Genes Dev 17, 2138-2150.
94. Jordens J, Janssens V, Longin S, Stevens I, Martens E, Bultynck G, Engelborghs Y, Lescrinier E, Waelkens E, Goris J, et al,. (2006) The protein phosphatase 2A phosphatase activator is a novel peptidyl-prolyl cis/trans-isomerase. J Biol Chem 281, 6349-6357.
95. Leulliot N, Vicentini G, Jordens J, Quevillon-Cheruel S, Schiltz M, Barford D, van Tilbeurgh H, &, Goris J, (2006) Crystal structure of the PP2A phosphatase activator: implications for its PP2A-specific PPIase activity. Mol Cell 23, 413-424.
96. Kong M, Fox CJ, Mu J, Solt L, Xu A, Cinalli RM, Birnbaum MJ, Lindsten T, &, Thompson CB, (2004) The PP2A-associated protein alpha4 is an essential inhibitor of apoptosis. Science 306, 695-698.
97. LeNoue-Newton M, Watkins GR, Zou P, Germane KL, McCorvey LR, Wadzinski BE, &, Spiller BW, (2011) The E3 ubiquitin ligase- and protein phosphatase 2A (PP2A)-binding domains of the Alpha4 protein are both required for Alpha4 to inhibit PP2A degradation. J Biol Chem 286, 17665-17671.
98. Nunbhakdi-Craig V, Schuechner S, Sontag JM, Montgomery L, Pallas DC, Juno C, Mudrak I, Ogris E, &, Sontag E, (2007) Expression of protein phosphatase 2A mutants and silencing of the regulatory B alpha subunit induce a selective loss of acetylated and detyrosinated microtubules. J Neurochem 101, 959-971.
99. McCluskey A, Sim AT, &, Sakoff JA, (2002) Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J Med Chem 45, 1151-1175.
100. Swingle MR, Amable L, Lawhorn BG, Buck SB, Burke CP, Ratti P, Fischer KL, Boger DL, &, Honkanen RE, (2009) Structure-activity relationship studies of fostriecin, cytostatin, and key analogs, with PP1, PP2A, PP5, and (beta12-beta13)-chimeras (PP1/PP2A and PP5/PP2A), provide further insight into the inhibitory actions of fostriecin family inhibitors. J Pharmacol Exp Ther 331, 45-53.
101. Cho US, Morrone S, Sablina AA, Arroyo JD, Hahn WC, &, Xu W, (2007) Structural basis of PP2A inhibition by small t antigen. PLoS Biol 5, e202.
102. Pallas DC, Shahrik LK, Martin BL, Jaspers S, Miller TB, Brautigan DL, &, Roberts TM, (1990) Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A. Cell 60, 167-176.
103. Kamibayashi C, Estes R, Lickteig RL, Yang SI, Craft C, &, Mumby MC, (1994) Comparison of heterotrimeric protein phosphatase 2A containing different B subunits. J Biol Chem 269, 20139-20148.
104. Li M, Guo H, &, Damuni Z, (1995) Purification and characterization of two potent heat-stable protein inhibitors of protein phosphatase 2A from bovine kidney. Biochemistry 34, 1988-1996.
105. Li M, Makkinje A, &, Damuni Z, (1996) The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem 271, 11059-11062.
106. Habrukowich C, Han DK, Le A, Rezaul K, Pan W, Ghosh M, Li ZG, Dodge-Kafka K, Jiang XJ, Bittman R, et al,. (2010) Sphingosine interaction with acidic leucine-rich nuclear phosphoprotein-32A (ANP32A) regulates PP2A activity and cyclooxygenase (COX)-2 expression in human endothelial cells. J Biol Chem 285, 26825-26831.
107. Gharbi-Ayachi A, Labbe JC, Burgess A, Vigneron S, Strub JM, Brioudes E, Van-Dorsselaer A, Castro A, &, Lorca T, (2010) The substrate of greatwall kinase, Arpp19, controls mitosis by inhibiting protein phosphatase 2A. Science 330, 1673-1677.
108. Mochida S, Maslen SL, Skehel M, &, Hunt T, (2010) Greatwall phosphorylates an inhibitor of protein phosphatase 2A that is essential for mitosis. Science 330, 1670-1673.
109. Kawabe T, Muslin AJ, &, Korsmeyer SJ, (1997) HOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2/M cell-cycle checkpoint. Nature 385, 454-458.
110. Saito S, Miyaji-Yamaguchi M, Shimoyama T, &, Nagata K, (1999) Functional domains of template-activating factor-I as a protein phosphatase 2A inhibitor. Biochem Biophys Res Commun 259, 471-475.
111. Adachi Y, Pavlakis GN, &, Copeland TD, (1994) Identification and characterization of set, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia. J Biol Chem 269, 2258-2262.
112. Saito S, Miyaji-Yamaguchi M, &, Nagata K, (2004) Aberrant intracellular localization of set-can fusion protein, associated with a leukemia, disorganizes nuclear export. Int J Cancer 111, 501-507.
113. Vonlindern M, Vanbaal S, Wiegant J, Raap A, Hagemeijer A, &, Grosveld G, (1992) Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3′ 1/2 to different genes-characterization of the set gene. Mol Cell Biol 12, 3346-3355.
114. Christensen DJ, Chen YW, Oddo J, Matta KM, Neil J, Davis ED, Volkheimer AD, Lanasa MC, Friedman DR, Goodman BK, et al,. (2011) SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. Blood 118, 4150-4158.
115. Cristobal I, Garcia-Orti L, Cirauqui C, Cortes-Lavaud X, Garcia-Sanchez MA, Calasanz MJ, &, Odero MD, (2012) Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematol-Hematol J 97, 543-550.
116. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, et al,. (2005) The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 8, 355-368.
117. Van Vlierberghe P, van Grotel M, Tchinda J, Lee C, Beverloo HB, van der Spek PJ, Stubbs A, Cools J, Nagata K, Fornerod M, et al,. (2008) The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood 111, 4668-4680.
118. Liu H, Gu Y, Wang H, Yin J, Zheng G, Zhang Z, Lu M, Wang C, &, He Z, (2015) Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer. Oncotarget 6, 14913-14925.
119. Janghorban M, Farrell AS, Allen-Petersen BL, Pelz C, Daniel CJ, Oddo J, Langer EM, Christensen DJ, &, Sears RC, (2014) Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. Proc Natl Acad Sci USA 111, 9157-9162.
120. Cristobal I, Rincon R, Manso R, Carames C, Zazo S, Madoz-Gurpide J, Rojo F, &, Garcia-Foncillas J, (2015) Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer. Clin Cancer Res 21, 347-356.
121. Anazawa Y, Nakagawa H, Furihara M, Ashida S, Tamura K, Yoshioka H, Shuin T, Fujioka T, Katagiri T, &, Nakamura Y, (2005) PCOTH, a novel gene overexpressed in prostate cancers, promotes prostate cancer cell growth through phosphorylation of oncoprotein TAF-l beta/SET. Cancer Res 65, 4578-4586.
122. Irie A, Harada K, Araki N, &, Nishimura Y, (2012) Phosphorylation of SET protein at Ser171 by protein kinase D2 diminishes its inhibitory effect on protein phosphatase 2A. PLoS One 7, e51242.
123. Arnaud L, Chen S, Liu F, Li B, Khatoon S, Grundke-Iqbal I, &, Iqbal K, (2011) Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET. FEBS Lett 585, 2653-2659.
124. Yu G, Yan T, Feng Y, Liu X, Xia Y, Luo H, Wang JZ, &, Wang X, (2013) Ser9 phosphorylation causes cytoplasmic detention of I2PP2A/SET in Alzheimer disease. Neurobiol Aging 34, 1748-1758.
125. Beisiegel U, Weber W, Ihrke G, Herz J, &, Stanley KK, (1989) The Ldl receptor related protein, Lrp, Is an apolipoprotein-e-binding protein. Nature 341, 162-164.
126. Kowal RC, Herz J, Goldstein JL, Esser V, &, Brown MS, (1989) Low-density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein-e-enriched lipoproteins. Proc Natl Acad Sci USA 86, 5810-5814.
127. Brown MS, &, Goldstein JL, (1986) A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34-47.
128. Avila EM, Holdsworth G, Sasaki N, Jackson RL, &, Harmony JAK, (1982) Apoprotein-e suppresses phytohemagglutinin-activated phospholipid turnover in peripheral-blood mononuclear-cells. J Biol Chem 257, 5900-5909.
129. Curtiss LK, &, Edgington TS, (1981) The biologic activity of the immunoregulatory lipoprotein, Ldl-in, is independent of its free fatty-acid content. J Immunol 126, 1382-1386.
130. Pepe MG, &, Curtiss LK, (1986) Apolipoprotein-e is a biologically-active constituent of the normal immunoregulatory lipoprotein, Ldl-In. J Immunol 136, 3716-3723.
131. Agarwal A, MacKenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW, Sears R, Vitek MP, Odero MD, Christensen DJ, et al,. (2014) Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res 20, 2092-2103.
132. Agarwal A, MacKenzie R, Oddo J, Vitek MP, Christensen DJ, &, Druker BJ, (2011) A novel SET antagonist (OP449) is cytotoxic to CML cells, including the highly-resistant BCR-ABL(T315I) mutant, and demonstrates enhanced efficacy in combination with ABL tyrosine kinase inhibitors. Blood 118, 1603-1604.
133. Christensen DJ, Ohkubo N, Oddo J, Van Kanegan MJ, Neil J, Li FQ, Colton CA, &, Vitek MP, (2011) Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A. J Immunol 186, 2535-2542.
134. Switzer CH, Cheng RYS, Vitek TM, Christensen DJ, Wink DA, &, Vitek MP, (2011) Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene 30, 2504-2513.
135. Suzuki S, Li XK, Enosawa S, &, Shinomiya T, (1996) A new immunosuppressant, FTY720, induces bcl-2-associated apoptotic cell death in human lymphocytes. Immunology 89, 518-523.
136. Suzuki S, Enosawa S, Kakefuda T, Shinomiya T, Amari M, Naoe S, Hoshino Y, &, Chiba K, (1996) A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation. Transplantation 61, 200-205.
137. Brinkmann V, (2009) FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol 158, 1173-1182.
138. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, et al,. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277, 21453-21457.
139. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, et al,. (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296, 346-349.
140. Matsuoka Y, Nagahara Y, Ikekita M, &, Shinomiya T, (2003) A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br J Pharmacol 138, 1303-1312.
141. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, et al,. (2007) FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 117, 2408-2421.
142. Roberts KG, Smith AM, McDougall F, Carpenter H, Horan M, Neviani P, Powell JA, Thomas D, Guthridge MA, Perrotti D, et al,. (2010) Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res 70, 5438-5447.
143. Dobrowsky RT, Kamibayashi C, Mumby MC, &, Hannun YA, (1993) Ceramide activates heterotrimeric protein phosphatase-2A. J Biol Chem 268, 15523-15530.
144. Hannun YA, &, Obeid LM, (2008) Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9, 139-150.
145. Kim SW, Kim HJ, Chun YJ, &, Kim MY, (2010) Ceramide produces apoptosis through induction of p27kip1 by protein phosphatase 2A-dependent Akt dephosphorylation in PC-3 prostate cancer cells. J Toxicol Environ Health A 73, 1465-1476.
146. Lin CF, Chen CL, Chiang CW, Jan MS, Huang WC, &, Lin YS, (2007) GSK-3 beta acts downstream of PP2A and the PI 3-kinase-Akt pathway, and upstream of caspase-2 in ceramide-induced mitochondrial apoptosis. J Cell Sci 120, 2935-2943.
147. Obeid LM, Linardic CM, Karolak LA, &, Hannun YA, (1993) Programmed cell-death induced by ceramide. Science 259, 1769-1771.
148. Mukhopadhyay A, Saddoughi SA, Song PF, Sultan I, Ponnusamy S, Senkal CE, Snook CF, Arnold HK, Sears RC, Hannun YA, et al,. (2009) Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J 23, 751-763.
149. Laine A, Sihto H, Come C, Rosenfeldt MT, Zwolinska A, Niemela M, Khanna A, Chan EK, Kahari VM, Kellokumpu-Lehtinen PL, et al,. (2013) Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov 3, 182-197.
150. Puustinen P, Rytter A, Mortensen M, Kohonen P, Moreira JM, &, Jaattela M, (2014) CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation. J Cell Biol 204, 713-727.
151. Guenebeaud C, Goldschneider D, Castets M, Guix C, Chazot G, Delloye-Bourgeois C, Eisenberg-Lerner A, Shohat G, Zhang M, Laudet V, et al,. (2010) The dependence receptor UNC5H2/B triggers apoptosis via PP2A-mediated dephosphorylation of DAP kinase. Mol Cell 40, 863-876.
152. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, Bottzauw T, Ala-Aho R, Nielsen C, Ivaska J, Taya Y, et al,. (2007) CIP2A inhibits PP2A in human malignancies. Cell 130, 51-62.
153. Bockelman C, Koskensalo S, Hagstrom J, Lundin M, Ristimaki A, &, Haglund C, (2012) CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer Biol Ther 13, 289-295.
154. Bockelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, Haglund C, Butzow R, &, Ristimaki A, (2011) Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer 105, 989-995.
155. Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu XL, Jonkers J, Ivaska J, Isola J, Darbon JM, et al,. (2009) CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 15, 5092-5100.
156. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ, &, Wang EH, (2011) CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 18, 857-865.
157. Fang YY, Li ZT, Wang XX, &, Zhang SL, (2012) CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis. Tumor Biol 33, 2299-2306.
158. He H, Wu G, Li WJ, Cao YC, &, Liu YF, (2012) CIP2A is highly expressed in hepatocellular carcinoma and predicts poor prognosis. Diagn Mol Pathol 21, 143-149.
159. Huang LP, Adelson ME, Mordechai E, &, Trama JP, (2010) CIP2A expression is elevated in cervical cancer. Cancer Biomark 8, 309-317.
160. Huang LP, Savoly D, Sidi AA, Adelson ME, Mordechai E, &, Trama JP, (2012) CIP2A protein expression in high-grade, high-stage bladder cancer. Cancer Med 1, 76-81.
161. Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, et al,. (2009) MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 101, 793-805.
162. Kikuno R, Nagase T, Ishikawa K, Hirosawa M, Miyajima N, Tanaka A, Kotani H, Nomura N, &, Ohara O, (1999) Prediction of the coding sequences of unidentified human genes. XIV. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res 6, 197-205.
163. Li WJ, Ge Z, Liu C, Liu ZF, Bjorkholm M, Jia JH, &, Xu DW, (2008) CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res 14, 3722-3728.
164. Qu W, Li WJ, Wei L, Xing LG, Wang XW, &, Yu JM, (2012) CIP2A is overexpressed in esophageal squamous cell carcinoma. Med Oncol 29, 113-118.
165. Rantanen T, Kauttu T, Akerla J, Honkanen T, Krogerus L, Salo J, Paavonen T, &, Oksala N, (2013) CIP2A expression and prognostic role in patients with esophageal adenocarcinoma. Med Oncol 30, 684.
166. Sung WW, Wang YC, Lin PL, Cheng YW, Chen CY, Wu TC, &, Lee H, (2013) IL-10 promotes tumor aggressiveness via upregulation of CIP2A transcription in lung adenocarcinoma. Clin Cancer Res 19, 4092-4103.
167. Vaarala MH, Vaisanen MR, &, Ristimaki A, (2010) CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res 29, 136.
168. Wiegering A, Pfann C, Uthe FW, Otto C, Rycak L, Mader U, Gasser M, Waaga-Gasser AM, Eilers M, &, Germer CT, (2013) CIP2A influences survival in colon cancer and is critical for maintaining Myc expression. PLoS One 8, e75292.
169. Yu GZ, Liu GH, Dong J, &, Jin YY, (2013) Clinical implications of CIP2A protein expression in breast cancer. Med Oncol 30, 524.
170. Zhai M, Cong L, Han YX, &, Tu GJ, (2014) CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion. Tumor Biol 35, 1123-1128.
171. Corson TW, &, Crews CM, (2007) Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell 130, 769-774.
172. Liu Z, Ma L, Wen ZS, Hu Z, Wu FQ, Li W, Liu JS, &, Zhou GB, (2014) Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer. Carcinogenesis 35, 905-914.
173. Liu Z, Ma L, Wen ZS, Cheng YX, &, Zhou GB, (2014) Ethoxysanguinarine induces inhibitory effects and downregulates CIP2A in lung cancer cells. ACS Med Chem Lett 5, 113-118.
174. Li WG, Dai FY, Cheng YX, Yin GF, Bi JL, &, Li DP, (2013) Identification of porcine reproductive and respiratory syndrome virus inhibitors through an oriented screening on natural products. Chem Res Chin Univ 29, 290-293.
175. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, &, Elliott PJ, (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59, 2615-2622.
176. Orlowski RZ, &, Kuhn DJ, (2008) Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14, 1649-1657.
177. Tseng LM, Liu CY, Chang KC, Chu PY, Shiau CW, &, Chen KF, (2012) CIP2A is a target of bortezomib in human triple negative breast cancer cells. Breast Cancer Res 14, R68.
178. Chen KF, Yeh PY, Hsu C, Hsu CH, Lu YS, Hsieh HP, Chen PJ, &, Cheng AL, (2009) Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-Kinase/Akt pathway. J Biol Chem 284, 11121-11133.
179. Chen KF, Pao KC, Su JC, Chou YC, Liu CY, Chen HJ, Huang JW, Kim I, &, Shiau CW, (2012) Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity. Bioorgan Med Chem 20, 6144-6153.
180. Arroyo JD, &, Hahn WC, (2005) Involvement of PP2A in viral and cellular transformation. Oncogene 24, 7746-7755.
181. Bryant JC, Westphal RS, &, Wadzinski BE, (1999) Methylated C-terminal leucine residue of PP2A catalytic subunit is important for binding of regulatory B alpha subunit. Biochem J 339, 241-246.
182. Ogris E, Gibson DM, &, Pallas DC, (1997) Protein phosphatase 2A subunit assembly: the catalytic subunit carboxy terminus is important for binding cellular B subunit but not polyomavirus middle tumor antigen. Oncogene 15, 911-917.
183. Lee J, Chen Y, Tolstykh T, &, Stock J, (1996) A specific protein carboxyl methylesterase that demethylates phosphoprotein phosphatase 2A in bovine brain. Proc Natl Acad Sci USA 93, 6043-6047.
184. Wei HJ, Ashby DG, Moreno CS, Ogris E, Yeong FM, Corbett AH, &, Pallas DC, (2001) Carboxymethylation of the PP2A catalytic subunit in Saccharomyces cerevisiae is required for efficient interaction with the B-type subunits CDC55p and RTS1p. J Biol Chem 276, 1570-1577.
185. Janssens V, Goris J, &, Van Hoof C, (2005) PP2A: the expected tumor suppressor. Curr Opin Genet Dev 15, 34-41.
186. Lee J, &, Stock J, (1993) Protein phosphatase-2a catalytic subunit is methyl-esterified at its carboxyl-terminus by a novel methyltransferase. J Biol Chem 268, 19192-19195.
187. Guenin S, Schwartz L, Morvan D, Steyaert JM, Poignet A, Madelmont JC, &, Demidem A, (2008) PP2A activity is controlled by methylation and regulates oncoprotein expression in melanoma cells: a mechanism which participates in growth inhibition induced by chloroethylnitrosourea treatment. Int J Oncol 32, 49-57.
188. Godeneche D, Rapp M, Thierry A, Laval F, Madelmont JC, Chollet P, &, Veyre A, (1990) DNA damage induced by a new 2-chloroethyl nitrosourea on malignant-melanoma cells. Cancer Res 50, 5898-5903.
189. Puustinen P, Junttila MR, Vanhatupa S, Sablina AA, Hector ME, Teittinen K, Raheem O, Ketola K, Lin S, Kast J, et al,. (2009) PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. Cancer Res 69, 2870-2877.
190. Bachovchin DA, Mohr JT, Speers AE, Wang C, Berlin JM, Spicer TP, Fernandez-Vega V, Chase P, Hodder PS, Schurer SC, et al,. (2011) Academic cross-fertilization by public screening yields a remarkable class of protein phosphatase methylesterase-1 inhibitors. Proc Natl Acad Sci USA 108, 6811-6816.
191. Bachovchin DA, Zuhl AM, Speers AE, Wolfe MR, Weerapana E, Brown SJ, Rosen H, &, Cravatt BF, (2011) Discovery and optimization of sulfonyl acrylonitriles as selective, covalent inhibitors of protein phosphatase methylesterase-1. J Med Chem 54, 5229-5236.
192. Seamon KB, Padgett W, &, Daly JW, (1981) Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci USA 78, 3363-3367.
193. Cristobal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, &, Odero MD, (2011) PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 25, 606-614.
194. Cristobal I, Rincon R, Manso R, Madoz-Gurpide J, Carames C, del Puerto-Nevado L, Rojo F, &, Garcia-Foncillas J, (2014) Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation. Biochim Biophys Acta 1842, 1823-1829.
195. Feschenko MS, Stevenson E, Nairn AC, &, Sweadner KJ, (2002) A novel cAMP-stimulated pathway in protein phosphatase 2A activation. J Pharmacol Exp Ther 302, 111-118.
196. Gutierrez A, Pan L, Groen RW, Baleydier F, Kentsis A, Marineau J, Grebliunaite R, Kozakewich E, Reed C, Pflumio F, et al,. (2014) Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. J Clin Invest 124, 644-655.
197. Kar S, Palit S, Ball WB, &, Das PK, (2012) Carnosic acid modulates Akt/IKK/NF-kappa B signaling by PP2A and induces intrinsic and extrinsic pathway mediated apoptosis in human prostate carcinoma PC-3 cells. Apoptosis 17, 735-747.
198. Birringer M, EyTina JH, Salvatore BA, &, Neuzil J, (2003) Vitamin E analogues as inducers of apoptosis: structure-function relation. Br J Cancer 88, 1948-1955.
199. Burton GW, &, Traber MG, (1990) Vitamin-E-antioxidant activity, biokinetics, and bioavailability. Annu Rev Nutr 10, 357-382.
200. Gu XB, Song XD, Dong YH, Cai H, Walters E, Zhang RS, Pang XW, Xie TP, Guo YH, Sridhar R, et al,. (2008) Vitamin E succinate induces ceramide-mediated apoptosis in head and neck squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 14, 1840-1848.
201. Lawson KA, Anderson K, Menchaca M, Atkinson J, Sun LZ, Knight V, Gilbert BE, Conti C, Sanders BG, &, Kline K, (2003) Novel vitamin E analogue decreases syngeneic mouse mammary tumor burden and reduces lung metastasis. Mol Cancer Ther 2, 437-444.
202. Neuzil J, Svensson I, Weber T, Weber C, &, Brunk UT, (1999) alpha-tocopheryl succinate-induced apoptosis in Jurkat T cells involves caspase-3 activation, and both lysosomal and mitochondrial destabilisation. FEBS Lett 445, 295-300.
203. Neuzil J, Tomasetti M, Zhao Y, Dong LF, Birringer M, Wang XF, Low P, Wu K, Salvatore BA, &, Ralph SJ, (2007) Vitamin E analogs, a novel group of "mitocans", as anticancer agents: the importance of being redox-silent. Mol Pharmacol 71, 1185-1199.
204. Qian M, Kralova J, Yu WP, Bose HR, Dvorak M, Sanders BG, &, Kline K, (1997) c-Jun involvement in vitamin E succinate induced apoptosis of reticuloendotheliosis virus transformed avian lymphoid cells. Oncogene 15, 223-230.
205. Wang XF, Dong LF, Zhao Y, Tomasetti M, Wu K, &, Neuzil J, (2006) Vitamin E analogues as anticancer agents: lessons from studies with alpha-tocopheryl succinate. Mol Nutr Food Res 50, 675-685.
206. You HH, Yu WP, Sanders BG, &, Kline K, (2001) RRR-alpha-tocopheryl succinate induces MDA-MB-435 and MCF-7 human breast cancer cells to undergo differentiation. Cell Growth Differ 12, 471-480.
207. Yu WP, Liao QY, Hantash FM, Sanders BG, &, Kline K, (2001) Activation of extracellular signal-regulated kinase and c-Jun-NH2-terminal kinase but not p38 mitogen-activated protein kinases is required for RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells. Cancer Res 61, 6569-6576.
208. Zhang Y, Ni J, Messing EM, Chang E, Yang CR, &, Yeh SY, (2002) Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc Natl Acad Sci USA 99, 7408-7413.
209. Neuzil J, Weber T, Schroder A, Lu M, Ostermann G, Gellert N, Mayne GC, Olejnicka B, Negre-Salvayre A, Sticha M, et al,. (2001) Induction of cancer cell apoptosis by alpha-tocopheryl succinate: molecular pathways and structural requirements. FASEB J 15, 403-415.
210. Huang PH, Wang DS, Chuang HC, Wei S, Kulp SK, &, Chen CS, (2009) alpha-Tocopheryl succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate cancer cells by targeting the PP2A-JNK-Sp1-signaling axis. Carcinogenesis 30, 1125-1131.